

nmd, a novel gene differentially expressed in human melanoma cell lines, encodes a new atypical member of the enzyme family of lipases

Jan J.M. van Groningen^a, Maarten R. Egmond^b, Henri P.J. Bloemers^a,
Guido W.M. Swart^{a,*}

^aDepartment of Biochemistry, University of Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

^bUnilever Research Laboratory, P.O. Box 114, 3130 AC Vlaardingen, The Netherlands

Received 18 November 1996; revised version received 23 January 1997

Abstract *nmd*, a novel gene, was isolated by applying the differential mRNA display method to human melanoma cell lines with different metastatic capacity. In a panel of 17 other human tumor cell lines, *nmd* RNA expression could only be detected at low levels in T24 (bladder carcinoma) and Caco-2 (colon adenocarcinoma). Furthermore, it was found in placenta and liver, but not in skin, colon, spleen, lung, muscle, prostate and kidney. Sequence analysis classified the *nmd* gene product as a new member of the enzyme family of lipases (almost 30% identity in amino acid sequence with other human lipases). Active site residues of lipases were conserved in NMD, but NMD lacks the regulatory lid domain, which controls entry to the active site in classical lipases. A similar deletion was earlier reported by others in the guinea pig pancreatic (phospho)lipase GPLRP2 and the phospholipase A1 from hornet venom (DolmI).

© 1997 Federation of European Biochemical Societies.

Key words: Human cutaneous melanoma; Differential display; Lipase; Guinea pig (phospho)lipase GPLRP2; 'Lid' domain

1. Introduction

The availability of excised lesions as well as cultured cells from different stages has made human cutaneous melanoma particularly suitable for studies of tumor progression [1]. Many changes in gene expression during progression of melanoma have been characterized (for a review see Weterman et al. [2]). The use of molecular markers in tumor diagnosis has become common practice. Moreover, identification of the function of various differentially expressed genes enhances our insight in tumor biology. Recently, we have applied the differential mRNA display technique on a panel of well-defined [3] human melanoma cell lines with different metastatic capacity when xenografted into nude mice. Thus, we isolated nine differentially expressed cDNAs, five of which represented novel gene products [4]. In this report we describe the characterization of one of them, *nmd*, encoding an unknown member of the enzyme family of lipases. The predicted NMD polypeptide lacks a so-called 'lid' domain, as was earlier described for guinea pig pancreatic (phospho)lipase GPLRP2 and the phospholipase A1 from hornet venom (DolmI) [5,6].

*Corresponding author. Fax (31) (24) 3540525.
E-mail: g.swart@bioch.kun.nl

Abbreviations: CoPLRP2, coypancreatic lipase related protein 2; GPLRP2, guinea pig pancreatic lipase-related protein 2

2. Materials and methods

2.1. Biological materials

Human melanoma cell lines MV3, BLM, 530 and 1F6 [3,7], T24 bladder carcinoma, PC-3 prostate adenocarcinoma, HeLa cervix carcinoma, MCF7 breast adenocarcinoma, Caco-2 colon adenocarcinoma, A-431 epidermoid carcinoma, HT-1080 fibrosarcoma, 143B PML BK TK and MG-63 osteosarcoma were grown as monolayers, whereas U-937 histiocytic lymphoma, K-562 chronic myelogenous leukemia, KG-1 acute myelogenous leukemia, JEG-3 choriocarcinoma, JAR placenta choriocarcinoma, MOLT-4 acute lymphoblastic leukemia, Raji Burkitt lymphoma, and Jurkat lymphoma were grown in suspension. All cell lines were grown in Dulbecco's modified Eagle's medium as described before [8]. Within the panel of melanoma cell lines, 1F6 and 530 represent poorly metastasizing cell lines, with a metastasis frequency of less than 10% 3 months after subcutaneous inoculation into nude mice. The cell lines BLM and MV3 represent the highly metastatic phenotype, with over 50% metastasis frequency [3]. Excision and processing of the human tissues was performed as described before [9].

2.2. RNA isolation and Northern blot analysis

Total RNA from human tissues and xenografts was isolated using the lithium-urea procedure as described by Auffray and Rougeon [10], whereas total RNA from cell lines was isolated using RNAzol solution (Tel-Test, Friendswood, TX). RNA oligo-deoxythymidine selections were performed using oligo-deoxythymidine columns (type II, Coll. Research, Bedford, MA). 10 µg of total RNA was glyoxylated [11], size fractionated on 1% agarose gels, and blotted onto Hybond N⁺ (Amersham, Aylesbury, UK). To confirm that equal amounts were loaded in each lane, the blots were afterwards hybridized with an 18S ribosomal RNA probe.

2.3. Construction of cDNA libraries

A cDNA library was constructed from 5 µg of oligo-deoxythymidine selected RNA from the poorly metastatic human melanoma cell line 530, using a λZap cDNA synthesis kit (Stratagene, La Jolla, CA) as described before [4].

2.4. DNA probes and hybridization

DNA probes were radiolabeled by the random prime labelling method by Feinberg and Vogelstein [12]. Hybridization of cDNA library was performed according to standard protocols [13].

2.5. DNA sequencing and computer analysis

DNA fragments were sequenced according to the dideoxy method as described by Sanger et al. [14] using a Sequenase sequencing kit (USB, Cleveland, OH). Large fragments were sequenced by constructing a set of deletion clones using exonuclease III (Erase-a-base kit, Promega, Madison, WI). Identification of known sequences was performed using the EMBL/Genbank database [15,16]. DNA sequence analysis, including searches for motifs, alignments, and structure predictions, was performed using the CAMMSA programs MOTIFS, PILEUP, CLUSTAL V, BESTFIT, PEPTIDESTRUCTURE, PLOT-STRUCTURE, and MEMBRANE PROPENSITY which are all part of the Wisconsin Package V 7.0 [15].

2.6. DNA isolation and Southern blot analysis

Chromosomal DNA was isolated according to the method of Blin




Fig. 1. Northern blot analysis of a panel of human melanoma cell lines (A) and xenografts (B). Total RNA samples (10 μ g) were loaded in each lane. Lane 1: BLM; lane 2: MV3; lane 3: 1F6; lane 4: 530. The blots were hybridized to radiolabeled 1.8 kb *nmd* cDNA insert of pJG454. The molecular weight marker was λ DNA digested with *Hind*III. As a check of the amount of RNA loaded in each lane an 18S ribosomal RNA hybridization is shown.

and Stafford [17]. DNA was digested with *Bam*HI, and 10 μ g was size fractionated on 0.6% agarose gels, transferred to Hybond N⁺ and hybridized as described previously for Northern blot analysis. To check for equal loading of DNA, the blot was hybridized afterwards to a chromosome 18-specific centromeric probe. No abnormalities involving chromosome 18 are known in relation with melanoma.

3. Results

3.1. Cloning and sequence analysis of *nmd*

Using the differential mRNA display technique we isolated nine cDNA clones, which were differentially expressed in human melanoma cell lines. One of these clones, clone 6, representing a gene designated *nmd*, showed a unique expression of a 1.9 kb transcript in the poorly metastatic human melanoma cell lines 530 and 1F6, and derived xenografts, whereas expression was not detected in the highly metastatic human melanoma cell lines MV3 and BLM, and xenografts derived from these cell lines (Fig. 1).

Screening of a cDNA library derived from cell line 530 resulted in the isolation of the *nmd* cDNA clone pJG454. The *nmd* cDNA sequence consists of 1767 nucleotides (U37591 GenBank). The longest open reading frame starting with a methionine codon at position 27 in the nucleotide sequence encodes a 456 amino acids long polypeptide (not shown).

Sequence analysis showed no identities with known genes or proteins, except for the 3' and 5' ends of a partially sequenced human cDNA clone 120969 with accession numbers T96131 and T96213 respectively. Similarities at the protein level could be detected with human and several other lipases. This is illustrated by the alignment of NMD with five different human lipases (Fig. 2). The overall identity of NMD with different human lipases is almost 30%.

Hydrophobicity plot analysis of the predicted amino acid sequence of NMD revealed a hydrophobic leader peptide with a putative signal cleavage site located 25 amino acids downstream of the translation start (Fig. 2). Potential *N*-glycosylation sites are located at positions 54 and 340, protein kinase C phosphorylation sites at positions 259, 344 and 379, and casein kinase II phosphorylation sites at positions -3, 74, 162, 175, 193, 244, 316 and 330. Furthermore a serine active site for lipase is located at position 141.

3.2. Northern blot analysis of *nmd* in human melanocytic lesions

Total RNA isolated from human melanocytic lesions was hybridized with the 1.8 kb *nmd* cDNA insert of pJG454 as a probe (Fig. 3). The expression of *nmd* mRNA could not be detected in normal skin (lane A) and three metastatic lesions (lanes K, L and M). A weak *nmd* expression was detected in cultured melanocytes (lane B), xenograft derived from radial growth phase (lane C) and vertical growth phase (lane D), and three metastatic lesions (lanes G, J and O), whereas expression was moderate to high in seven out of 13 metastatic lesions (lanes E, F, H, I, N, P and Q).

3.3. Expression of *nmd* is restricted to a few human organs and tumor cell lines

A Northern blot containing total RNA from gut, spleen, placenta, liver, muscle, lung, prostate, kidney cortex and kidney medulla was hybridized with the 1.8 kb *nmd* cDNA insert of pJG454 as a probe (Fig. 4). Expression of *nmd* was only detected in placenta (lane 3) and liver (lane 4). For further characterization a Northern blot containing total RNA from 17 different human tumor cell lines was screened with the *nmd* cDNA insert. No expression was

nmd	MPPGPWESCF	WVGGILWLWS	VGSSG	/ /	DAPPT	PQPKCADFQS	ANLFEGETDLK	V---QFLLFV	PSNPSCGQLV	42	
hPL	L LWTL LL	LGAVAG-	/ /	KEV	CYERLGCFS	DS WSGITER	PLHILPWSP	DVNTR	YT NE NNF E	53	
hPLRP1	LIFWTITLE	LL AAKG	/ /	KEV	CYEDLGCFS	TE WGGTAIR	PLKILPWSPE	KIGTR	YT NE NNF IL	53	
hPLRP2	L PWTLGLL	LLATVRG	/ /	KEV	CYQQLGCFS	EKPWAGTLQR	PVKLLPWSPE	DIDTR	YT NE NNF I	53	
hHL	DTS LCFSI	LLVLC FIQS	SAL	/ /	GQSLK E	FGRR QAVE	T KTLHEMK-	---TR	G ET -QGC IR	42	
hLPL	ESKALLVLT	LAVY QSLTA	SRGGVAA	/ /	ADQ	RRDFIDIES-	-----	---K A RT	PETAEDTCH	28	
								*****	* * *		
nmd	EG--SSDLQN	-SGFNATLGT	KLIIHGFRVL	GTKPSWIDTF	IRTLRRA--T	NANVIAVDWI	YGSTGVYFSA	VKNVIKLSLE		117	
hPL	AADS ISGS	--N KTNRK	RF	-ID KGEEN	LANV	CKN FKV--E	SV C C	K G RTG TQ	SQ IRIVGA	128	
hPLRP1	LLSDP TIEA	- N QMDRK	RF	-ID KGDE	VTDM	CKK FEV--E	EV C C	K K QAT TQ	AN RVVGAQ	129	
hPLRP2	TGTEPDTIEA	- N QLDRK	RF	-LD KAED	PSDM	CKKMFV--E	KV C C	R H RAM TQ	Q IRVVAQ	129	
hHL	INHPTLQEC	-- SS PL	VM	WS D	VLEN	WQM	VAA KSQPAQ	PV GL	TLAHDH TI	R TRLVGK	120
hLPL	LIPGVAESVA	TCH HSSK	FMV	WT T	MYE	VPKL	VAA YKREPD	S- V	L SRAQEH	PVS AGYTKLVGQD	107
nmd	ISLFLNKLIV	-LGVSESSIH	IIGVSLGAHV	GGMVQLFGG	Q--LGQITGL	DPAGPEYTRA	SVEERLDAGD	ALFVEAHTD		194	
hPL	VAY VEF QS	AF Y P NV	V H	A A EA	RRTN	T I R	E CFQGT	PELV	PS K DV	206	
hPLRP1	VAQM DI T	EYSYPP KV	L H	A EA	SKTP	- SR	VEASFEST	PE V	PS D DV	206	
hPLRP2	TAFLIQA ST	Q Y LEDV	V H	T AAEA	RRL	- RV R	CFQDE	PE V	PS V DV	207	
hHL	VVAL RW EE	SVQL R HV	L Y	V S FA	SSI	THKI R	A LFEGS	APSN	SPD S D F	200	
hLPL	VAR I WMEE	EFNYPLDNV	LL Y	A A IA	S --T	NKKVNR	NFEY	EAPS	SPD D DVL F	185	
nmd	TD-----NL	GIRIPVGEVD	YFVNGGQDQP	GC-----	---PTFFYAG	YSYLICDEMR	AVHLYISALE	NSCPLM-AFP		256	
hPL	GAPIVPNLGF	MSQV L F P	VEM	KKNILSQI	VDIDGIWEGT	RDFAA N L	SYKY TDSIV	PDGFA G		285	
hPLRP1	AAPLIPFLGF	TNQOM L F P	ESM	KKNALSQI	VDLDGIWAGT	RDFVA N L	SYKY LESIL	PDGFA Y		285	
hPLRP2	SSPIVPSLGF	MSQK L F P	KEM	KKNVLSTI	TDIDGIWEGI	GGFVS N L	SFEY S SVL	PDGFL GY		286	
hHL	REHMG LSV	KQ I Y	FYP SF	HFLLEYRH	IAHQG- N I	TQTIK S E	S F DS L	HAGTQSM Y		278	
hLPL	RGSPG RSI	QK	IYP TF	NIGEAIRV	IAERGL-GDV	DQLVK S E	SI F DS L	EENPSK YR		263	
nmd	CASYKAFLAG	RCLDCFNPF	LSCPRIGLVE	QGGVKIEPLP	KEVKVYLLTT	SSAPYCMHHS	LVEFHLKELR	NKDTNIEVT-		335	
hPL	NV T N K	FP PSG--	-G QM HYA	-DRYPGKTND	VGQ F D G	DASNFAWRWY	K SVT SGKK	VTGHILVSL-		360	
hPLRP1	T S ESD	K FP PDQ--	-G QM HYA	-DKFAGRTSE	EQQ FF N G	EASNFAWRWY	G SIT SGRT	ATGQIKVAL-		360	
hPLRP2	DE QES	K FP PDE--	-G KM HYA	-DQF GKTSYA	V QTFN N G	ESGNFTSWRY	K SVT SGKE	KVNGY RIAL		362	
hHL	GDMNS SQ	L S KKG--	-R NTL YHV	ROEPRSRS--	--KRLF V R	AQS FKVY Y	QLKIQF-INQ	TETFIQTTFT		350	
hLPL	S KE EK	L S RKN--	-R NNL YEI	NKVRAKRS--	--S M K R	QM KVF Y	Q KI FSGTE	SETHTNQAFE		336	
nmd	---FLSSNIT	SSSKITIPKQ	QRYGKGI--	-AHATPQCQI	NQVKFKFQSS	NRV---WKKD	-----R	TTII-----		391	
hPL	GNKGN-	-----	YEIF TL--	-KPDSTHSNE	FDSVDVVDGL	QM KFI Y-N	NV-----	I NPTL-----		412	
hPLRP1	GNKGN	-----H	YSIFR L--	-KPGSTHSNE	FDA LDVGTI	EK KFL -NN	NV-----	I NPTL-----		412	
hPLRP2	YG NEN-	-----	YEIF SL--	-KPDASHTCA	ID D NVGKI	QK KFL -NK	RG-----	I NLSE-----		414	
hHL	MSLLGTKE--	----- M	KIPITLGGK	IASNKTYSP	ITLDVDIGEL	IMIKFK ENS	AVWANVWDTV	Q PWSTGP		420	
hLPL	ISLYGTVA--	-----ES	ENIPFTLPE-	VSTNKTYSP	IYTEVDIGEL	LMLK KSD	SYFS--WSD-	-----WWSSP		397	
nmd	--GKFTALL	PVNDREKMCV	LPEPVNLQAS	VTVSCD-L						426	
hPL	--PRVGASKI	I ETNVG---	-K-QF FCSP	E REEV	LT LTTPC					449	
hPLRP1	--P VGATKI	T QKG E---	-KTVY FCSE	D RE T	LT LTTPC					450	
hPLRP2	--P LGASQI	T QSG D---	-GTEY FCSD	D EENV	QS LYPC					452	
hHL	RHSGLVLKTI	R KAG T---	-QQRMTFCSE	N --D	L LR	PTQEKIFVKC	EIKSKTSKRK	IR		476	
hLPL	---GFAIQKI	R KAG T---	-QKK IFCSR	EK --SH	QK	GKAPAVFVKC	HDKSLNKKSG			448	

Fig. 2. Alignment of the predicted protein NMD with the other human lipases (hPL: human pancreatic lipase; hPLRP1: human pancreatic lipase-related protein 1; hPLRP2: human pancreatic lipase related protein 2; hHL: human hepatic lipase; hLPL: human lipoprotein lipase). Published sequences of other human lipases [28-32] are compared with our sequence. The alignment starts with the leader peptide and the cleavage sites are indicated by slashes (/). Numbering starts from the first amino acids of the mature products. Identical amino acids are indicated by empty spaces, amino acid deletions by dashes (-). Conservation of amino acids is indicated by an asterisk (*) above and below the sequences; bold in the case of a conservation in at least five out of six sequences. See text for further details.

found in cell lines derived from carcinomas of the prostate, cervix and breast or from choriocarcinoma, epidermoid carcinoma, lymphoma and myeloid leukemia. In T24 cells (bladder carcinoma) and Caco-2 cells (colon carcinoma), the 1.8 kb *nmd* transcript was only detected at low levels (results not shown).

4. Discussion

This paper describes the characterization of *nmd*, a novel gene, expressed in two melanoma cell lines with a low metastatic potential and in xenografts derived from these cell lines. Expression was absent in two highly metastatic cell lines and




Fig. 3. Northern blot analysis of human cutaneous lesions. Total RNA samples (10 μ g) were loaded in each lane. Lane A: normal skin (13 biopsies from 12 patients); lane B: melanocytes; lane C: xenograft derived from radial growth phase; lane D: xenograft derived from vertical growth phase; lanes E–Q: melanoma metastatic lesions. The blot was hybridized to radiolabeled 1.8 kb *nmd* cDNA insert of pJG454. The molecular weight marker was λ DNA digested with *Hind*III. As a check of the amount of RNA loaded in each lane an 18S ribosomal RNA hybridization is shown. Densitometric scanning showed that the maximum variation in 18S rRNA loading (between lanes K and C) was not more than 3-fold, whereas this was 50-fold for *nmd* mRNA (between lanes N and G, lanes A, K, L and M being negative).

derived xenografts (Fig. 1). The differences in *nmd* mRNA expression between poorly and highly metastasizing melanoma cell lines cannot be ascribed to gene amplification or other major chromosomal rearrangements, as demonstrated by Southern blot analysis (results not shown).

Sequence analysis revealed that *nmd* is a novel gene encoding a 50 kDa protein, which probably represents a new member of the enzyme family of lipases [5,18,19]. The similarity with other lipases is sufficiently high to classify NMD as an α/β -hydrolase-fold enzyme [20,21]. Amino acid residues 135–145 (IHIIGVSLGAH), centered around Ser-141, are completely homologous to the consensus for the active site of lipases (Fig. 2). Beside Ser-141, NMD also contains two other active site residues (Asp-165 and His-235) and the oxyanion residue Phe-66. When compared to other human lipases, NMD is characterized by a deletion of 11 amino acids between Cys-220 and Pro-221. The deleted sequence constitutes a large part of the so-called lid domain of the other lipases (Fig. 2). The lid domain or 'flap' regulates access to the active site of the classical pancreatic lipase [19]. A similar deletion is present in guinea pig pancreatic (phospho)lipase GPLRP2 and in phospholipase A1 from hornet venom (DolmI), two other member of the lipase family [6]. In the absence of an aggregated lipid substrate, the lid domain prevents access to the active site. In the presence of water-insoluble substances, the lid domain as well as another surface loop (the so-called β 5 loop) undergo large conformational changes thus opening access to the active site and creating the oxyanion hole [5,19,21]. In GPLRP2, containing a 'mini-lid', the catalytic site is freely accessible, and it displays a high phospholipase activity [5,6]. In the pancreatic (phospho)lipase of the coypu (coypu pancreatic lipase-




Fig. 4. Northern blot analysis of several human organs. Total RNA samples (10 μ g) were loaded in each lane. Lane 1: colon; lane 2: spleen; lane 3: placenta; lane 4: liver; lane 5: smooth muscle; lane 6: lung; lane 7: prostate; lane 8: kidney. The blot was hybridized to radiolabeled 1.8 kb *nmd* cDNA insert of pJG454. The molecular weight marker was λ DNA digested with *Hind*III. As a check of the amount of RNA loaded in each lane an 18S ribosomal RNA hybridization is shown.

related protein 2 or CoPLRP2), the lid domain is not deleted, but the stabilizing interactions observed in classical pancreatic lipase between the lid domain, the protein core and the β 5 loop, are missing. The observed similarities suggest that NMD represents a new branch in the gene family of lipases and possesses an inherent phospholipase activity.

During evolution guinea pig and coypu, both South American rodents, have lost the metabolic enzyme phospholipase A₂ [22,23]. It is speculated that the atypical substrate specificity of GPLRP2 and CoPLRP2, caused by a deletion in the lid domain, compensates for this loss [6,24]. Our discovery of *nmd* in the human genome indicates that the use of a 'lidless' lipase is not confined to a few exceptional species.

Among the cell lines and tissues tested expression of *nmd* was restricted to some human melanoma cell lines and lesions, as well as to human liver and placenta and, only at low levels, to the tumor cell lines T24 and Caco-2. The expression profiles of *nmd* mRNA in human melanoma cell lines and derived xenografts suggest it to be a potential marker for early stages of melanoma progression. Its presence, however, in a considerable number of human melanoma metastatic lesions seems to be in contrast with this suggestion. It is remarkable that other potential early progression markers, notably *nm23* [25], *nma* [26] and *nmb* [27] display a similar expression distribution. Genes like *nm23*, *nma*, *nmb* and also *nmd* may be involved in attenuating metastatic properties of melanoma cells, possibly as a consequence of tumor-host interactions. Tumor progression may require that genes are (temporarily) switched off in the course of metastasis, but sometimes turned on again later in a secondary, distantly growing tumor [4,26].

Acknowledgements: We thank Dr. Goos van Muijen and Ms. Ine Cornelissen (Department of Pathology, University Hospital Nijmegen) for xenografts and human cutaneous lesions.

References

- [1] Herlyn, M., Clark, W.H., Rodeck, U., Mancianti, M.L., Jambrosic, J. and Koprowski, H. (1987) *Lab. Invest.* 56, 461–474.
- [2] Weterman, M.A., van Muijen, G.N., Bloemers, H.P. and Ruiter, D.J. (1994) *Lab. Invest.* 70, 593–608.
- [3] van Muijen, G.N., Cornelissen, L.M., Jansen, C.F., Figdor, C.G., Johnson, J.P., Brocker, E.B. and Ruiter, D.J. (1991) *Clin. Exp. Metastasis* 9, 259–272.
- [4] van Groningen, J.J.M., Bloemers, H.P.J. and Swart, G.W.M. (1995) *Cancer Res.* 55, 6237–6243.
- [5] Hjorth, A., Carriere, F., Cudrey, C., Woldike, H., Boel, E., Lawson, D.M., Ferrato, F., Cambillau, C., Dodson, G.G., Thim, L. and Verger, R. (1993) *Biochemistry* 32, 4702–4707.

- [6] Withers-Martinez, C., Carriere, F., Verger, R., Bourgeois, D. and Cambillau, C. (1996) *Structure* 4, 1363–1374.
- [7] van Muijen, G.N., Jansen, K.F., Cornelissen, I.M., Smeets, D.F., Beck, J.L. and Ruiters, D.J. (1991) *Int. J. Cancer* 48, 85–91.
- [8] Weterman, M.A., Stoop, G.M., van Muijen, G.N., Kuznicki, J., Ruiters, D.J. and Bloemers, H.P. (1992) *Cancer Res.* 52, 1291–1296.
- [9] Weterman, M.A., van Muijen, G.N., Bloemers, H.P. and Ruiters, D.J. (1993) *Cancer Res.* 53, 6061–6066.
- [10] Auffray, C. and Rougeon, F. (1980) *Eur. J. Biochem.* 107, 303–314.
- [11] McMaster, G.K. and Carmichael, G.G. (1977) *Proc. Natl. Acad. Sci. USA* 74, 4835–4838.
- [12] Feinberg, A.P. and Vogelstein, B. (1983) *Anal. Biochem.* 132, 6–13.
- [13] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- [14] Sanger, F., Coulson, A.R., Barrell, B.G., Smith, A.J. and Roe, B.A. (1980) *J. Mol. Biol.* 143, 161–178.
- [15] Devereux, J., Haerberli, P. and Smithies, O. (1984) *Nucleic Acids Res.* 12, 387–395.
- [16] Pearson, W.R. and Lipman, D.J. (1988) *Proc. Natl. Acad. Sci. USA* 85, 2444–2448.
- [17] Blin, N. and Stafford, D.W. (1976) *Nucleic Acids Res.* 3, 2303–2308.
- [18] Giller, T., Buchwald, P., Blum-Kaelin, D. and Hunziker, W. (1992) *J. Biol. Chem.* 267, 16509–16516.
- [19] Carriere, F., Thirstrup, K., Hjorth, S. and Boel, E. (1994) *FEBS Lett.* 338, 63–68.
- [20] Ollis, D.L., Cheah, E., Cygler, M., Dijkstra, B., Frolow, F., Franken, S.M., Harel, M., Remington, S.J., Silman, I., Schrag, J., Sussman, J.L., Verschueren, K.H. and Goldman, A. (1992) *Protein Eng.* 5, 197–211.
- [21] Cambillau, C., Longhi, S., Nicolas, A. and Martinez, C. (1996) *Curr. Opin. Struct. Biol.* 6, 449–455.
- [22] Fauvel, J., Bonnefis, M.J., Chap, H., Thouvenot, J.P. and Douste-Blazy, L. (1981) *Biochim. Biophys. Acta* 666, 72–79.
- [23] Thirstrup, K., Verger, R. and Carriere, F. (1994) *Biochemistry* 33, 2748–2756.
- [24] Carriere, F., Thirstrup, K., Boel, E., Verger, R. and Thim, L. (1994) *Protein Eng.* 7, 563–569.
- [25] Steeg, P.S., Bevilacqua, G., Sobel, M.E. and Liotta, L.A. (1991) *Basic Life Sci.* 57, 355–360.
- [26] Degen, W.G., Weterman, M.A., van Groningen, J.J., Cornelissen, I.M., Lemmers, J.P., Agterbos, M.A., Geurts van Kessel, A., Swart, G.W. and Bloemers, H.P. (1996) *Int. J. Cancer* 65, 460–465.
- [27] Weterman, M.A., Ajubi, N., van Dinter, I.M., Degen, W.G., van Muijen, G.N., Ruiters, D.J. and Bloemers, H.P. (1995) *Int. J. Cancer* 60, 73–81.
- [28] Lowe, M.E., Rosenblum, J.L. and Strauss, A.W. (1989) *J. Biol. Chem.* 264, 20042–20048.
- [29] Giller, T., Buchwald, P., Blum-Kaelin, D. and Hunziker, W. (1992) *J. Biol. Chem.* 267, 16509–16516.
- [30] Datta, S., Luo, C.-C., Li, W.-H., van Tuinen, P., Ledbetter, D., Brown, M.A., Chen, S.-H., Liu, S.-w. and Chan, L. (1988) *J. Biol. Chem.* 263, 1107–1110.
- [31] Wion, K.L., Kirchgessner, T.G., Lusic, A.J., Schotz, M.C. and Lawn, R.M. (1987) *Science* 235, 1638–1641.
- [32] Jennens, M.L. and Lowe, M.E. (1995) *J. Lipid Res.* 36, 1029–1036.